New HIV vaccine candidate enters first human safety trial
NCT ID NCT06905275
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This early-stage study tests two experimental HIV vaccines (UVAX-1107 and UVAX-1197) in 25 healthy adults without HIV. The main goals are to check if the vaccines are safe and to see how the immune system reacts. Participants will receive injections and have blood and lymph node samples taken over about a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS (#31788)
Birmingham, Alabama, 35222, United States
-
Columbia P&S CRS (#30329)
New York, New York, 10032, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
Vanderbilt Vaccine (VV) CRS (#30352)
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.